Redirection to the bone marrow improves T cell persistence and antitumor functions.
Redirection to the bone marrow improves T cell persistence and antitumor functions.
复制标题
DOI:
10.1172/jci97454
复制
发表时间:
2018-05-01
期刊:
影响因子:
--
通讯作者:
Chakraverty R
中科院分区:
文献类型:
--
作者:
Khan AB;Carpenter B;Santos E Sousa P;Pospori C;Khorshed R;Griffin J;Velica P;Zech M;Ghorashian S;Forrest C;Thomas S;Gonzalez Anton S;Ahmadi M;Holler A;Flutter B;Ramirez-Ortiz Z;Means TK;Bennett CL;Stauss H;Morris E;Lo Celso C;Chakraverty R
A key predictor for the success of gene-modified T cell therapies for cancer is the persistence of transferred cells in the patient. The propensity of less differentiated memory T cells to expand and survive efficiently has therefore made them attractive candidates for clinical application. We hypothesized that redirecting T cells to specialized niches in the BM that support memory differentiation would confer increased therapeutic efficacy. We show that overexpression of chemokine receptor CXCR4 in CD8+ T cells (TCXCR4) enhanced their migration toward vascular-associated CXCL12+ cells in the BM and increased their local engraftment. Increased access of TCXCR4 to the BM microenvironment induced IL-15–dependent homeostatic expansion and promoted the differentiation of memory precursor–like cells with low expression of programmed death-1, resistance to apoptosis, and a heightened capacity to generate polyfunctional cytokine-producing effector cells. Following transfer to lymphoma-bearing mice, TCXCR4 showed a greater capacity for effector expansion and better tumor protection, the latter being independent of changes in trafficking to the tumor bed or local out-competition of regulatory T cells. Thus, redirected homing of T cells to the BM confers increased memory differentiation and antitumor immunity, suggesting an innovative solution to increase the persistence and functions of therapeutic T cells.